Table 2.
Meta-analysis results of NLR, PLR, and LMR and OS/CSS and EFS in patients with ESCC
| OS/CSS | EFS | |||||||
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| N | HR (95% CI), P | I2 (%), P | Begg’s P, Egger’s P | N | HR (95% CI), P | I2 (%), P | Begg’s P, Egger’s P | |
|
| ||||||||
| NLR | ||||||||
| Overall | 22 | 1.54 (1.39, 1.74), <0.001 | 53.9, 0.001 | 0.17, 0.06 | 11 | 1.34 (1.22, 1.46), <0.001 | 20, 0.253 | 0.31, 0.17 |
| Subgroup analysis Cutoff value | ||||||||
| ≥3 | 12 | 1.71 (1.47, 1.98), <0.001 | 40.1, 0.07 | 0.16, 0.12 | 6 | 1.43 (1.25, 1.63), <0.001 | 0.0, 0.516 | 1.00, 0.44 |
| <3 | 10 | 1.41 (1.21, 1.64), <0.001 | 57.3, 0.01 | 0.37, 0.65 | 5 | 1.26 (1.11, 1.43), <0.001 | 39.0, 0.161 | 0.81, 0.47 |
| Sample size | ||||||||
| ≥200 | 13 | 1.45 (1.28, 1.64), <0.001 | 49.9, 0.02 | 0.95, 0.56 | 6 | 1.36 (1.20, 1.53), <0.001 | 0.0, 0.693 | 0.45, 0.16 |
| <200 | 9 | 1.89 (1.47, 2.44), <0.001 | 61.7, 0.01 | 0.86, 0.01 | 5 | 1.55 (1.09, 2.20), 0.015 | 56.8, 0.055 | 0.81, 0.23 |
| Treatment | ||||||||
| Surgery-based | 15 | 1.43 (1.27, 1.61), <0.001 | 45.7, 0.03 | 0.14, 0.27 | 9 | 1.31 (1.18, 1.46), <0.001 | 22.2, 0.245 | 0.35, 0.09 |
| CRT | 7 | 1.78 (1.55, 2.04), <0.001 | 37.0, 0.14 | 1.00, 0.63 | 2 | 1.41 (1.18, 1.69), <0.001 | 42.8, 0.186 | – |
| Country | ||||||||
| China | 14 | 1.48 (1.30, 1.69), <0.001 | 55.0, 0.01 | 0.74, 0.75 | 8 | 1.41 (1.25, 1.58), <0.001 | 4.9, 0.392 | 0.90, 0.47 |
| Non-China | 8 | 1.77 (1.39, 2.25), <0.001 | 57.4, 0.02 | 0.92, 0.02 | 3 | 1.22 (1.05, 1.42), 0.011 | 33.7, 0.221 | 0.30, 0.59 |
| PLR | ||||||||
| Overall | 12 | 1.37 (1.25, 1.51), <0.001 | 33.1, 0.125 | 0.84, 0.32 | 5 | 1.27 (1.07, 1.52), 0.007 | 26.9, 0.242 | 0.62, 0.69 |
| Cutoff value | ||||||||
| ≥150 | 5 | 1.58 (1.33, 1.88), <0.001 | 12.4, 0.36 | 0.46, 0.13 | 3 | 1.26 (1.00, 1.59), 0.05 | 10.5, 0.33 | 0.30, 0.26 |
| <150 | 7 | 1.29 (1.15, 1.44), <0.001 | 26.0, 0.23 | 0.23, 0.14 | 2 | 1.72 (0.69, 4.29), 0.24 | 68.9, 0.07 | – |
| Sample size | ||||||||
| ≥200 | 7 | 1.40 (1.20, 1.64), <0.001 | 51.2, 0.06 | 0.76, 0.51 | 3 | 1.25 (1.04, 1.51), 0.02 | 7.3, 0.34 | 1.00, 0.44 |
| <200 | 5 | 1.38 (1.03, 1.85), 0.03 | 3.9, 0.385 | 0.81, 0.07 | 2 | 1.73 (0.64, 4.68), 0.28 | 67.6, 0.08 | – |
| Treatment | ||||||||
| Surgery-based | 9 | 1.39 (1.16, 1.68), <0.001 | 48.0, 0.05 | 0.60, 0.36 | 5 | 1.27 (1.07, 1.52), 0.007 | 26.9, 0.242 | 0.62, 0.69 |
| CRT | 3 | 1.44 (1.20, 1.72), <0.001 | 0.0, 0.705 | 1.00, 0.94 | – | – | – | – |
| Country | ||||||||
| China | 9 | 1.42 (1.22, 1.66), <0.001 | 48.8, 0.05 | 0.60, 0.22 | 4 | 1.29 (1.07, 1.55), 0.01 | 43, 0.15 | 0.73, 0.64 |
| Non-China | 3 | 1.31 (0.92, 1.86), 0.134 | 0.0, 0.68 | 1.00, 0.904 | 1 | 1.13 (0.66, 1.94), 0.66 | – | – |
| LMR | ||||||||
| Overall | 6 | 0.70 (0.54, 0.89), 0.004 | 64.0, 0.02 | 0.02, 0.05 | 3 | 0.65 (0.43, 0.99), 0.04 | 75.2, 0.02 | 0.12, 0.06 |
| Cutoff value | ||||||||
| ≥3.5 | 3 | 0.80 (0.56, 1.10), 0.17 | 70.0, 0.04 | 1.00, 0.58 | 2 | 0.67 (0.33, 1.35), 0.26 | 86.9, 0.01 | – |
| <3.5 | 3 | 0.59 (0.46, 0.77), <0.001 | 0.0, 0.54 | 0.30, 0.17 | 1 | 0.61 (0.42, 0.89), 0.01 | – | – |
| Sample size | ||||||||
| ≥200 | 4 | 0.83 (0.73, 0.95), 0.008 | 49.5, 0.11 | 0.09, 0.36 | 2 | 0.77 (0.50, 1.18) | 67.1, 0.08 | – |
| <200 | 2 | 0.47 (0.32, 0.69), <0.001 | 0.0, 0.70 | – | 1 | 0.46 (0.31, 0.69) | – | – |
| Country | ||||||||
| China | 5 | 0.74 (0.58, 0.93), 0.012 | 62.4, 0.03 | 0.03, 0.14 | 3 | 0.65 (0.43, 0.99), 0.04 | 75.2, 0.02 | 0.12, 0.06 |
| Non-China | 1 | 0.42 (0.21, 0.83), 0.013 | – | – | 0 | – | – | – |
| Treatment | ||||||||
| Surgery | 5 | 0.75 (0.59, 0.95), 0.017 | 58.4, 0.05 | 0.03, 0.12 | 2 | 0.77 (0.50, 1.18), 0.23 | 67.1, 0.08 | – |
| CRT | 1 | 0.50 (0.32, 0.78), 0.002 | – | – | 1 | 0.46 (0.31, 0.69), <0.001 | – | – |
Abbreviations: CRT, chemoradiotherapy; CSS, cancer-specific survival; EFS, event-free survival; OS, overall survival; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; LMR, lymphocyte to monocyte ratio; ESCC, esophageal squamous cell carcinoma.